1. Introduction {#s0005}
===============

Amongst mouse IgG subclasses, IgG2a and IgG2b are considered to be the most potent activators, and dominate in successful passive transfer experiments in both murine infection (including malaria), and murine tumour models ([@b0035; @b0140; @b0220]). Such functional distinctions have been attributed to differences in their capacity to fix complement and/or recruitment of relevant Fc-receptors for IgG (FcγRs) ([@b0140]). However, very few studies have compared epitope-matched IgG subclasses in the context of protection from both communicable and non-communicable diseases ([@b0030; @b0060; @b0085; @b0130; @b0180; @b0185; @b0190; @b0235]), and in these studies, disease-specific effects were observed between IgG subclasses. For example, mouse IgG1 has been shown to be poor at killing tumours, yet plays an important role in controlling gastrointestinal parasites ([@b0120; @b0250]). Mouse IgG1 is believed not to be a subclass associated with protective properties as it is not a potent complement activator and it possesses an extremely low activation to inhibition (A:I) ratio (0.1 compared to 69 and 7 for IgG2a and IgG2b respectively), as a consequence of its preference for binding the inhibitory FcγRIIB receptor ([@b0255]). Work with non-epitope matched mouse monoclonal antibodies (mAbs) targeting *Plasmodium yoelii* MSP1~19~ has shown conflicting data, with some IgG1 mAbs protecting from malaria (e.g. mAb G3), and others (e.g. mAb B4), having little or no effect on the course of disease ([@b0220]). However, in the absence of epitope-matched reagents, it is difficult to directly compare the efficacy of IgG1 against the other subclasses in the protection from blood-stage malaria. Due to structural and functional differences between the murine IgG subclasses (in particular with respect to FcγRs they bind), and to attempt to resolve existing controversies as to whether FcRs are indeed even required for protection from malaria in the mouse, we generated two panels of recombinant mouse IgG1, IgG2a, IgG2b and IgG3 targeting identical epitopes on *Plasmodium falciparum* and *P. yoelii* MSP1~19~ ([Fig. 1](#f0005){ref-type="fig"}). These were then used to investigate the anti-malarial properties of the mouse subclasses *in vivo*.

2. Materials and methods {#s0010}
========================

2.1. Generation of *Pf*MSP1~19~-specific antibodies {#s0015}
---------------------------------------------------

### 2.1.1. Construction of pVL-C1-mouse kappa light chain {#s0020}

For all primer sequences, nucleotides in bold refer to restriction enzyme sites whereas an underline highlights stop codons. The plasmid pVL-C1-mouse kappa was generated by a three step PCR. Primer pairs VL-C1for (5′ GGC ***GTG CAC*** TCC GAT ATT GTG ATG ACC CAG 3′) and k-joint-rev (5′ ggg aag atg gat aca gtt ggt gca gca tca gtt c 3′) were used to amplify the VL by PCR from pVKExpress C1, whilst introducing an *Apa*L1 restriction site on the 5′ end. A second PCR with primer pairs k-joint-for (5′ gaa ctg atg ctg cac caa ctg tat cca tct tcc c 3′) and MK-rev (5′ g***ac tag t***cc ct[c ta]{.ul}a cac tca ttc ctg ttg a 3′) containing a *Spe*I were used to amplify the mouse kappa light chain constant region from BALB/c genomic DNA. Overlap PCR with primer pairs VL-C1for and MK-rev were then used to fuse as a single PCR product the VL of C1 and the mouse kappa constant region, which was then cloned in pCR2.1-Topo (parking vector) prior to sub-cloning into the parental pVKExpress C1 ([@b0125; @b0150]) as an *ApaL*I/*Spe*I fragment.

### 2.1.2. Construction of pVH-C1-mIgG1 {#s0025}

pVH-C1-IgA1 ([@b0215]) was digested with *Sal*I to remove the IgA constant region sequence and re-ligated to produce pVH-C1-delIgA1. This plasmid was then digested with *BssH*II/*Xba*I to release the VH of C1 which was then sub-cloned into pcDNA3.1-C1-hIgG1 from which the C1 and hIgG1 sequences were previously deleted (pcDNA3.1-delC1delIgG1) using the same restriction sites to create pcDNA3.1-C1-delhIgG1. The murine IgG1 constant region was amplified from BALB/c genomic DNA using primer pairs Mg1-for (containing an *Xba*I site) (5′ GCA AAA GAG CGG CCT ***TCT AGA*** AGG TTT G 3′) and Mg1-rev (5′ CAC TGG GA[T CA]{.ul}T TTA CCA GGA GAG TG 3′), and cloned into the parking vector, prior to sub-cloning as an *Xba*I fragment into pcDNA3.1-C1-delhIgG1 to generate pVH-C1-mIgG1.

### 2.1.3. Construction of pVH-C1-mIgG2a {#s0030}

Primer pairs Mg2a-for (5′ ***G GTC ACC*** ATC AAG AGG AGG AAG 3′) and Mg2a-rev (5′ ***TCT AGA*** GC[T CA]{.ul}T TTA CCC GGA GT 3′) were used to amplify the murine IgG2a from genomic DNA whilst introducing a *BstE*II site 5′ of the CH1 and an *Xba*I site 3′ of the stop codon respectively and cloned into the parking vector. pVH-C1-hIgG1 was digested with *Sal*I and blunted with T4 DNA polymerase (New England Biolabs) prior to recovery from gels, and digestion with *Xba*I, into which a *BstE*II blunted/XbaI fragment from the parking vector was ligated to create pVH-C1-mIgG2a.

### 2.1.4. Construction of pVH-C1-mIgG2b and IgG3 {#s0035}

Primer pairs Mg2b-for (5′ ***GAT ATC*** GGT CAC AGT GCA AGC TCT 3′) and Mg2b-rev (5′***TCT AGA*** GC[T CA]{.ul}T TTA CCC GGA G[A]{.ul} 3′) were used to amplify the murine IgG2b from genomic DNA whilst introducing an *EcoR*V site 5′ of the CH1 and an *Xba*I site 3′ of the stop codon respectively and cloned into the parking vector. pVH-C1-hIgG1 was digested with *BamH*I and blunted with T4 DNA polymerase (New England Biolabs) prior to recovery from gels, and digestion with *Xba*I, into which an *EcoR*V blunted/*Xba*I fragment from the parking vector was ligated to create pVH-C1-mIgG2b. Primer pairs Mg3-for (5′ ***GAT ATC*** GTT CAG GAT AGA GCT GGG 3′) and Mg3-rev (5′ ***TCT AGA*** TC[T CA]{.ul}T TTA CCA GGG GA 3′) were used in the same way to generate pVH-C1-mIgG3.

2.2. Generation of *Py*MSP1~19~-specific antibodies {#s0040}
---------------------------------------------------

### 2.2.1. Construction of pVL-B10-mouse kappa light chain {#s0045}

pVL-C1-mouse kappa light chain was digested with *ApaL*I/*Xho*I to release the VL of C1. The VL of B10 was subcloned as an *ApaL*I/*Xho*I fragment derived from the parental expression vector pB10-VL/10 ([@b0170]).

### 2.2.2. Construction of pVH-B10-mIgG2a {#s0050}

pVH-C1-mIgG2a and parental plasmid pB10-VH/5 ([@b0170]) were digested with *BssH*II/*BstE*II to release the VH of C1 (pVH-delC1-mIgG2a) and the VH of B10 respectively. The VH of B10 was sub-cloned into pVH-delC1-mIgG2a using the same restriction sites and renamed pVH-B10-mIgG2a.

### 2.2.3. Construction of pVH-B10-mIgG1 {#s0055}

The plasmid pVH-B10-mIgG1 was generated in two steps. pVH-C1-mIgG1 and pVH-B10-mIgG2a were digested with *BssH*II/*BstE*II to release the VH of C1 and VH of B10 respectively. The VH of B10 was sub-cloned into pVH-delC1-mIgG1. Due to the presence of a second *BstE*II site in exon 1 (CH1 domain) 160 bp after the VH of B10 3′ *BstE*II site, both plasmids were digested with *BstE*II and the released fragment sub-cloned into pVH-B10delC1-mIgG1 with the same restriction sites to generate pVH-B10-mIgG1.

### 2.2.4. Construction of pVH-B10-mIgG2b and IgG3 {#s0060}

pVH-B10-mIgG2a was partially digested with *Mfe*I/*Xba*I to release the IgG2a (pVH-B10-delmIgG2a) sequence after the VH of B10. IgG2b and IgG3 were released from their respective parking vectors with *EcoR*I/*Xba*I and sub-cloned into pVH-B10-delmIgG2a compatible cohesive restriction site ends (*Mfe*I--*EcoR*I) and *Xba*I. The newly generated expression vectors were renamed as pVH-B10-mIgG2b and pVH-B10-mIgG3. All plasmids were sequenced in both directions to confirm that no errors were introduced into either the variable or constant region genes during PCR/cloning. Amino acid translation of the VH and VL genes for both C1 and B10 expressed in the mouse IgGs confirmed that they are indeed epitope-matched and are shown in [Fig. 2](#f0010){ref-type="fig"}.

2.3. Protein expression and purification {#s0065}
----------------------------------------

Chinese hamster ovary (CHO)-K1 or human embryonic kidney (HEK)-293T cells were transfected by electroporation with corresponding heavy- and light-chain plasmids and the Abs were expressed as follows: IgG1 on HEK-293T and IgG2a, IgG2b, and IgG3 on CHO-K1. Positive clones secreting MSP1~19~-specific IgG detected by ELISA, on plates coated with recombinant *Pf*MSP1~19~-GST ([@b0015]) or *Py*MSP1~19~-GST ([@b0110]), or immuno-blotting using goat anti-mouse IgG-Fc (Pierce), goat anti-mouse IgG1, IgG2a, IgG2b or IgG3 (Southern Biotech), or a goat anti-mouse kappa (Southern Biotech) all conjugated to horse radish peroxidase (HRP) as previously described ([@b0170]). From large-scale cultures, mouse IgG was purified on HiTrap protein G-Sepharose (GE Healthcare) by FPLC. The integrity and purity of the antibodies were verified on 4--12% SDS--PAGE gradient gels (Invitrogen).

2.4. Immunofluorescence assay (IFA) and surface plasmon resonance (SPR) analysis {#s0070}
--------------------------------------------------------------------------------

For IFAs, washed erythrocytes from mice infected with the transgenic (Tg) parasite Pb-PfM19 described by [@b0045], were fixed on slides in methanol--acetone (1:1, vol/vol) for 10 min. After being blocked in phosphate buffered saline (PBS)/5% (vol/vol) goat serum, slides were incubated with Abs at 5 μg ml^−1^ in blocking buffer for 1 h, washed, then incubated for 1 h with fluorescein isothiocyanate (FITC)-conjugated goat F(ab′)~2~ anti-human IgG (Sigma or Caltag) or goat anti-mouse IgG γ-chain specific (Southern Biotech) diluted 1:500 in blocking buffer. After washing, slides were mounted with DAPI anti-fade and Ab binding examined by IF microscopy on a Zeiss Axioscope 40 microscope. For SPR, quantitative association (*K*~A~) and dissociation (*K*~D~) constants of the mouse IgG subclasses were measured using a BIAcore X Machine (GE Healthcare). Antigen (*Pf*MSP1~19~-GST) at a concentration of 50 μg/ml was amine-coupled onto a dextran matrix CM5 sensor chip using a Pharmacia Biosensor Amine Coupling Kit following the manufacturer's instructions. Various concentrations of purified IgGs were then injected into a final volume of 50 μL at a rate of 10 μL/min over the chip and binding kinetics analysed using BIAsimulation 3.0 software.

2.5. Luminol chemiluminescence assay of respiratory burst and myeloperoxidase release {#s0075}
-------------------------------------------------------------------------------------

Neutrophils were isolated from heparinized blood taken from healthy volunteers by the sedimentation of erythrocytes in 6% (w/v) dextran T70 (GE Healthcare) in 0.9% (w/v) saline at 37 °C for 30 min, followed by leucocyte separation on a discontinuous density gradient of Lymphoprep (*ρ* = 1.077 g/cm^3^; Nycomed, Birmingham, UK) over Ficoll-Hypaque (*ρ* = 1.119 g/cm^3^), centrifuged at 700*g* for 20 min at room temperature. Approval for the collection and use of human cells was obtained from the local Queen's Medical Centre ethics committee. Wells of chemiluminescence microtiter plates (Dynatech Laboratories, Billinghurst, Sussex, UK) were coated with 150 μl of *Pf*MSP1~19~ at 5 μg ml^−1^ in coating buffer (0.1 M carbonate buffer, pH 9.6) and incubated overnight at 4 °C. After washing three times with PBS, 150 μl of anti-*Pf*MSP1~19~ IgG at 100 or 50 μg ml^−1^ was added to antigen coated wells. In each case, triplicate wells were prepared and left for 2 h at room temperature. After washing as before, 100 μl of luminol \[67 μg ml^−1^ in Hank's buffered saline solution (HBSS) containing 20 mM HEPES and 0.1 g/100 ml globulin-free BSA (HBSS/BSA)\] was added to each well. After the addition of 50 μl of purified neutrophils (10^6^/ml in HBSS/BSA) to each well, plates were transferred to a Microlumat LB96P luminometer, and the chemiluminescence was measured at 2 min intervals for 120 min at 37 °C. Data were analysed using Excel software.

2.6. Passive immunization and parasite challenge {#s0080}
------------------------------------------------

Pathogen-free BALB/c mice from 6 to 8 weeks of age (caged individually) were used to test *in vivo* efficacy of mouse IgG1 in passive transfer experiments. IgG1 was administered (0.5 mg/injection) intraperitoneally (i.p.) on day −1, 0, and +1. Mice were challenged with 5000 parasitized red blood cells (prbc) with Pb-PfM19b that were administered i.p. 5 h after Ab injection on day 0. From day +2 mice were screened daily for weight loss and % infected erythrocytes (parasitemia) counted by blood smears stained with Giemsa (Sigma). At the end of the experiment or when mice lost more than 20% of their initial weight, the animals were humanely sacrificed. All animal experiments were approved by the Home Office and performed in accordance with UK guidelines and regulations (PPL 40/2753).

3. Results {#s0085}
==========

3.1. Characterization of *Pf*MSP1~19~-specific mouse IgG1, IgG2a, IgG2b and IgG3 {#s0090}
--------------------------------------------------------------------------------

*Pf*MSP1~19~ and *Py*MSP1~19~-specific mouse IgG1, IgG2a, IgG2b and IgG3 were secreted into culture supernatants from stably transfected CHO-K1 or HEK-293T cells. These recombinant antibodies recognized either recombinant *Pf*MSP1~19~ or *Py*MSP1~19~ by ELISA with polyclonal anti-mouse IgG Fc- or kappa light chain-specific secondary reagents ([Fig. 3](#f0015){ref-type="fig"}a and b). To check that each cell line only secreted the intended antibody class, a second sandwich ELISA was developed to confirm the subclass of the secreted IgG antibodies ([Fig. 3](#f0015){ref-type="fig"}c and d). Here we focus on the *Pf*MSP1~19~-specific mouse IgG1, IgG2a, IgG2b and IgG3 that were purified from CHO-K1 or HEK-293T culture supernatants by protein-G affinity-chromatography and appeared pure by SDS--PAGE analysis ([Fig. 4](#f0020){ref-type="fig"}a). Total yields of protein after purification, dialysis, and concentration from numerous different batches of culture supernatant over several time points were in the region of 15 mg from 30 l of supernatant for IgG1, and 2.8 mg, 2.1 mg, 1.5 mg from 7 l of supernatant for IgG2a, IgG2b and IgG3 respectively. The poor yields of IgG2a, IgG2b and IgG3 were most likely a consequence of these subclasses being cloned into a different expression plasmid (pVHExpress) compared to the mouse IgG1 (pcDNA3.1), and therefore the majority of work described focuses on IgG1 for which a sufficient quantity of antibody was derived for *in vivo* studies. The mouse IgG antibodies had an apparent molecular weight (MW) of approximately 150 kDa, although there were minor differences in the MW dependent on subclass. All the preparations contained a significant proportion of free heavy and light chains (arrowed), suggesting that not all the expressed protein folded into intact heterodimeric antibody. Western blotting with the IgG subclass-specific reagents used in the detecting ELISAs were unable to detect any of the mouse IgGs by immunoblotting on both non-reducing and reducing gels, although an alternative polyclonal goat anti-mouse IgG-Fc did recognize mouse IgG1, IgG2a and very faintly IgG2b ([Fig. 4](#f0020){ref-type="fig"}b). No significant binding to mouse IgG3 was observed with this reagent despite the presence of an equivalent amount of protein. Importantly, surface plasmon resonance (SPR) analysis for all the IgG subclasses generated revealed no reduction in affinity for *Pf*MSP1~19~ when compared with the parental human IgG1 antibody ([Table 1](#t0005){ref-type="table"} and [Fig. 5](#f0025){ref-type="fig"}), the binding constants remaining essentially the same for each subclass. The recombinant mouse IgG1 by indirect IFA produced a characteristic pattern of MSP1 reactivity from *P. falciparum* infected erythrocytes (not shown) and *Plasmodium berghei* parasites Tg for *Pf*MSP1~19~ ([Fig. 6](#f0030){ref-type="fig"}, bottom right corner, arrowed).

3.2. IgG1 triggers *Pf*MSP1~19~-specific neutrophil nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activation through FcγR cross-linking {#s0095}
-----------------------------------------------------------------------------------------------------------------------------------------------------

We next assessed the ability of the mouse IgG1 to interact with FcγRs and induce NADPH oxidase activation (respiratory burst) and degranulation in blood neutrophils ([Fig. 7](#f0035){ref-type="fig"}). For neutrophils, luminol chemiluminescence provides a read out of NADPH oxidase activation and myeloperoxidase release ([@b0165; @b0170]). When attached to *Pf*MSP1~19~-GST-coated plates, the mouse IgG1 induced comparable respiratory bursts to the parental human IgG1 ([Fig. 7](#f0035){ref-type="fig"}), suggesting that binding to *Pf*MSP1~19~ allows mouse IgG1 to be presented to neutrophil FcγRs in an optimal configuration for receptor cross-linking and triggering of functional responses. This finding is similar to that reported previously with a different mouse IgG1 (mAb 12.10) also recognizing *Pf*MSP1~19~ ([@b0105]). Since mouse IgG1 is known to bind to human FcγRIIA but not to FcγRIII, the activation of these neutrophils most likely occurs through binding to the former receptor ([@b0170]).

3.3. Passive transfer of mouse IgG1 into wild type mice has no effect on the course of a rodent malaria infection {#s0100}
-----------------------------------------------------------------------------------------------------------------

Despite binding *Pf*MSP1~19~ with high affinity, passive transfer of mouse IgG1 into WT BALB/c mice failed to protect seven out of eight animals, in two separate experiments, from a challenge infection with blood-stage *P. berghei* parasites Tg for *Pf*MSP1~19~ ([Fig. 8](#f0040){ref-type="fig"}).

4. Discussion {#s0105}
=============

Although we have previously shown that mice Tg for human FcRs are very useful for investigating human antibody function *in vivo*, particularly where there are no suitable animal models for *P. falciparum* infection in humans ([@b0125; @b0215]), an argument can be made that they are somewhat contrived, and therefore should be compared in parallel experiments in wild type models of murine malaria infection with murine antibodies. Here we describe the construction of two panels of mouse IgG1, IgG2a, IgG2b and IgG3 recognizing identical epitopes in *Pf*MSP1~19~ or *Py*MSP1~19~.

*Plasmodium* spp. merozoites attach to the surface of red blood cells by means of different surface antigens; among these antigens is MSP1 ([@b0075]). This surface antigen is cleaved twice; the first cleavage takes place at schizogony followed by a second cleavage to reveal *Pf*MSP1~19~ just prior to invasion ([@b0005; @b0135]). This 19-kDa peptide is relatively conserved with few polymorphic variants and has been described as a major candidate for vaccine development ([@b0160]), and continues to be the subject of study for immune therapy ([@b0195]).

These epitope-matched antibodies were generated by cloning variable genes from mAbs previously shown to confer passive protection from rodent malarias ([@b0125; @b0220]), into newly generated expression constructs containing mouse IgG1, IgG2a, IgG2b and IgG3 constant region genes respectively. The original plan was to generate the panel of mouse IgGs with the same expression plasmid (pcDNA3.1). However, due to the presence of a *BstE*II site on the C-terminal site of the VH-C1 in the parental human expression plasmid, we could not find a suitable enzyme site with which releases the human IgG1 sequence from the expression vector and subclones all the mouse IgG sequences in. The approach taken to generate the IgG2a, IgG2b, and IgG3-C1 Abs was to sub-clone in the murine sequences in an expression plasmid (pVHExpress) previously used in the expression of anti-malarial Abs ([@b0125]). These plasmids were expressed in CHO-K1 or HEK-293T cells, and all eight secreted antibodies generated were shown to bind their respective MSP1~19~ antigen, and were identified as belonging to the correct subclass by ELISA ([Fig. 2](#f0010){ref-type="fig"}).

CHO and HEK-293 mammalian cell lines are widely used in the production of recombinant proteins ([@b0260]). Predominantly in industry, CHOs have been used to express a wide range of recombinant proteins including antibodies used in the treatment of numerous diseases, including: multiple sclerosis, arthritis and cancer ([@b0080; @b0100]). To a lesser extent, HEK-293s have also been used in the industry to produce recombinant antibodies, but alongside CHOs, they have been the subject of study for increased productivity in the field ([@b0260]). HEK-293s have been used to express recombinant proteins for studies in neurology, electrophysiology and to produce mAbs amongst other therapeutic proteins ([@b0025; @b0230]). Functional IgGs need to be glycosylated in their Fc-fragment in order to have Fc-mediated effector functions ([@b0095; @b0240]), although we have not directly assessed the glycosylation status of these reagents, CHO and HEK-293 cell lines have been previously shown to effectively secrete Abs with N-linked carbohydrates ([@b0205; @b0210]).

The mouse IgG1, IgG2a, IgG2b and IgG3 all bound *Pf*MSP1~19~ with high affinity as determined by surface plasmon resonance analysis ([Fig. 4](#f0020){ref-type="fig"}). The panel of IgG antibodies bound with comparable affinity to recombinant *Pf*MSP1~19~ in line with previous observations with other antibodies ([@b0125]), and the mouse IgG1 bound to native protein as determined by immunofluorescence microscopy with infected erythrocytes ([Fig. 6](#f0030){ref-type="fig"}). Previous results have shown that the parental human IgG1 from which these mouse antibodies were derived is dependent on FcR-mediated recruitment for function, and that inhibition of erythrocyte invasion and/or inhibition of MSP1 processing are/is not the principal mechanism through which this antibody controls parasites ([@b0125]).

Typically in passive transfer experiments with rodent malarias, large concentrations of antibody (1.5 mg total dose per mouse, given as three individual doses) have to be given to provide protection. Although we could produce sufficient quantities of all the antibody classes to allow for preliminary *in vitro* comparisons to be made, we could only generate sufficient mIgG1 with which to do *in vivo* work. Intriguingly, passive transfer experiments with this IgG1 antibody failed to protect BALB/c mice from challenge infection with malaria parasites ([Fig. 8](#f0040){ref-type="fig"}). Although the mouse IgG1 was fully functional, as determined by its ability to induce NADPH mediated oxidative bursts from human neutrophils, the antibody was ineffective at controlling the development of malaria when passively transferred into BALB/c mice that were challenged with the Tg parasite Pb-PfM19 ([@b0045]). In contrast to mouse IgG2a or IgG2b, mouse IgG1 binds preferentially to inhibitory FcγRIIB (CD32B) expressed on murine macrophages, monocytes and B cells ([@b0145; @b0175]), but not on neutrophils, offering a possible explanation as to why this subclass was found to be ineffective at controlling the development of a lethal malaria infection when passively transferred into recipient mice.

The similarities of the genomes of the human and rodent *Plasmodium* spp. with their 14 chromosomes, ranging from 23 to 27 Mb, coding for over 5000 proteins from which around 80% of the +5300 genes found in these genomes are orthologous, highlight the importance of murine malarias as models to understand the human disease ([@b0050; @b0070; @b0090]). These genetic similarities have led to the development of targeted gene knock-outs, mutations, fluorescently-tagged, generation of 'reporter' or 'attenuated' parasites that contribute to the development of reliable vaccines against the disease ([@b0090]). To date, 561 rodent parasite mutants (predominantly *P. berghei*) have been reported (Rodent Malaria genetically modified Parasites DataBase (RMgmDB) <http://www.pberghei.eu/> accessed on 11th August 2011).

The use of Tg *P. berghei* rodent parasites expressing vaccine-candidate Ags from orthologous genes of *P. falciparum* has been described for a wide range of proteins and genes, such as the: sporozoite adhesive protein TRAP ([@b0245]), circumsporozoite protein (CSP) ([@b0155; @b0225]), the chloroquine resistance transporter (CRT) ([@b0055]), and the UIS4 and HT1 genes that code for a parasitophorous vacuole membrane protein in sporozoites and liver stages (expressed in a Tg *P. yoelii*) and a hexose transporter, respectively ([@b0010; @b0115]).

Parasites Tg for MSP1~19~ are no exception. Rodent parasite *Plasmodium chabaudi* MSP1~19~ has been expressed in *P. falciparum* and used for *in vitro* studies ([@b0040]), and two Tg rodent *P. berghei* parasites expressing *Pf*MSP1~19~ have been described: Pb-PfM19 and PfMSP1--19Pb~8.7~ ([@b0020; @b0045]) (respectively). Passive immunization of human IgG1 anti-*Pf*MSP1~19~ in BALB/c mice challenged and infected with Pb-PfM19, protected CD64-Tg mice (but not WT mice) from the course of infection ([@b0125]). Similar results were found in mice immunized with purified rabbit anti-*Pf*MSP1~42~ IgG where sterile protection was also observed ([@b0200]). However, alternatively from these experiments, passive transfer of Abs 12.8 and 12.10 into BALB/c mice challenged with Pb-PfM19 confirmed their inability to protect *in vivo* suggesting that the presence of six amino acids of *P. berghei*'s MSP1~19~ in the Tg parasite was required for both mAbs to be able to bind to the *Pf*MSP1~19~ epitope ([@b0105]). These discrepant results from passive transfer experiments in infections with Pb-PfM19 have encouraged us to assess the efficacy of the alternate panel of IgGs targeting *Py*MSP1~19~ to elucidate their response in a more natural model of infection.

From 1965 to 2010, more than 1900 immunization studies have been conducted involving all four rodent *Plasmodium* spp. and human parasites in feasible vaccine development trials. In this vast amount of time and research, many combinations of treatments have been studied such as: (1) immunizations with live, attenuated or dead parasites, (2) purified proteins such as Ags, Abs, DNA subunits, via multiple routes of delivery ([@b0065]). Passive transfer experiments *in vivo* looking at the efficacy of Abs in controlling malaria continue to be of interest as still, the mechanisms of action of the Fc-portion of Abs in controlling the disease is not completely understood. Current improvements in the mass production of recombinant proteins could allow IgG therapies to become the standard choice of treatment against blood-stage malaria in the near future. It is of our interest to continue this project and aim to increase the yield of purified Abs from transfected mammalian cell lines by expressing our panel of IgGs in Sp2/0 myelomas for instance. With greater yields of purified Abs, we would be able to complete the *in vitro* characterization of the remaining -C1 Abs and compare *in vivo* both panels of the epitope-matched IgGs constructed.

In summary, two panels of epitope-matched mouse IgGs (IgG1, IgG2a, IgG2b, and IgG3) targeting *Pf*MSP1~19~ or *Py*MSP1~19~ were constructed and expressed in mammalian cell lines. A novel *Pf*MSP1~19~-specific mouse IgG1 did not show protective capability against parasite challenge in mice but was shown to be fully functional *in vitro*. Whilst this finding may indicate that IgG1 does not play a major role in protection against malaria, we cannot rule out the possibility that the findings reflect certain shortcomings of the *Pf*MSP1~19~ Tg *P. berghei* rodent malaria model used, hence future work aims to investigate the role of the other IgG subclasses generated using the anti-*P. yoelii* panel of antibodies described herein.
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![Generating two panels of epitope-matched murine IgG Abs specific for MSP1~19~ epitopes C1 (*P. falciparum*-*Pf*MSP1~19~) or B10 (*P. yoelii*-*Py*MSP1~19~). Diagram represents a general overview to the construction of (a) C1 and (b) B10 mouse IgGs. Variable genes from parental mAbs C1 or B10 were sub-cloned into redesigned expression vectors for each of the mouse IgG subclasses.](gr1){#f0005}

![Sequencing of C1 and B10 VH and VL genes. Amino acid sequences alignment of *Pf*MSP1~19~ and *Py*MSP1~19~-binding epitope-matched mouse IgGs with the respective parental expression plasmids. (a) pVL-C1-mouse kappa compared with pVKExpress C1. (b) IgG1, IgG2a, IgG2b, and IgG3-C1 mouse IgG constructs compared with (h)IgG1-C1. (c) pVL-B10-mouse kappa compared with pB10-VL/10. (d) IgG1, IgG2a, IgG2b, and IgG3-B10 mouse IgG constructs compared with pB10-VH/5.](gr2){#f0010}

![ELISA screening of *Pf*MSP1~19~ and *Py*MSP1~19~-specific mouse IgGs. HEK-293T or CHO-K1 mammalian cell lines were stably-transfected by electroporation with expression plasmids coding for the panel of mouse IgGs targeting *P. falciparum* or *P. yoelii* MSP1~19~. Clones secreting antigen-specific IgGs were detected by enzyme-linked immunosorbent assay (ELISA). Five micrograms of recombinant purified antigen *Pf*MSP1~19~ (a) or *Py*MSP1~19~ (b) was coated and secreting clones detected with an anti-mouse IgG Fc-specific (HC) or anti-mouse kappa light chain (LC) secondary antibodies. To confirm the secretion of the panel of C1 (c) or B10 (d) epitope-matched mouse IgGs a capture ELISA was performed. Plates were coated with goat anti-mouse F(ab′)~2~ and supernatant from secreting clones analysed with subclass-specific secondary antibodies. All secondary reagents used were HRP conjugated and all plates were read at 450 nm. Bars represent the mean OD values from duplicate or triplicate wells. Supernatant from untransfected cells was used as negative control. Two micrograms of mAb B10 was used as positive control on panel b. Error bars represent Standard Deviation (SD).](gr3){#f0015}

![Characterization of purified recombinant *Pf*MSP1~19~-specific epitope-matched mouse IgGs. Characterization of the purified *Pf*MSP1~19~-specific mouse IgGs. KEY: IgG1 (A), IgG2a, (B), IgG2b (C), IgG3 (D). (a) Five micrograms of each Ab was run on NuPAGE 4--12% Bis--Tris SDS gels (Invitrogen) under denaturing non-reducing conditions (A--D) or denaturing reducing conditions (E--H) and compared with the control antibody human IgG1 (JS1) from which they were derived (IDEM). An expected MW of ∼150 kDa for the intact antibodies was shown (arrowed, 'IgG') although free constitutive heavy chains and light chain were observed (50 and 25 kDa respectively, arrowed). (b) Western Blot analysis of the IgG samples transferred into PVDF membranes. Analysis was made following the same conditions and sample order described on (a). Murine IgG1, IgG2a-C1 antibodies were clearly detectable with polyclonal anti-mouse IgG Fc-specific secondary antibody compared to IgG2b which was detected very faintly, but none of them with the subclass-specific secondary antibodies used in ELISA.](gr4){#f0020}

![Surface plasmon resonance (SPR)-derived association and dissociation curves of mouse IgGs binding to *Pf*MSP1~19~. SPR association (*K*~A~) and dissociation (*K*~D~) curves of mouse IgG binding to recombinant purified antigen *Pf*MSP1~19~ amine-coupled and immobilized to a CM5 sensor chip. The antibodies were injected into flow at five different concentrations of 2 μM (red), 1 μM (green), 0.5 μM (cyan), 0.25 μM pink), and 0.125 μM (dark blue) at time 0 and replaced with buffer alone at the times indicated with arrows. No binding was seen from any of the IgGs onto control Ag coated in flow cell 2. Data are summarized in [Table 1](#t0005){ref-type="table"}. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)](gr5){#f0025}

![Characterization of purified mouse IgG1-C1 by immunofluorescence assay (IFA). Mouse IgG1 is reactive with MSP1~19~ on methanol--acetone-fixed smears of merozoites and erythrocytes infected with rodent *P. berghei* Tg for *P. falciparum* MSP1~19~ (Pb-PfM19). Top panel: mAbs 12.8 and 12.10 previously described and known not to bind to Pb-PfM19 ([@b0105]) and B10 anti-*Py*MSP1~19~ as negative control ([@b0220]). Bottom panel: Human IgG1-C1 (JS1) and human IgG1-e9 (JS2) as previously described ([@b0125]) and murine IgG1-C1 bind Pb-PfM19 infected erythrocytes. Binding was visualized by staining with a FITC-conjugated secondary reagent with nuclei stained with DAPI and assessed by fluorescent microscopy under 40× magnification.](gr6){#f0030}

![Mouse *Pf*MSP1~19~-specific IgG1 is functional. Neutrophil NADH oxidative bursts were measured by adding antibodies to a chemiluminescence plate coated with recombinant purified antigen *Pf*MSP1~19~. Relative Light Units (RLU, arbitrary units of light produced/second) were calculated from triplicate wells using neutrophils as previously described ([@b0125; @b0165; @b0170]). Each point in the graph represents the mean value of triplicate wells. RLU were measured for over 120 min after the IgGs were added to neutrophils at two different concentrations of 50 (△) or 100 (○) μg/ml of mIgG1-C1. The overall response was comparable to that derived from human IgG1-C1 at the same concentrations (▴, ● 50 or 100 μg/ml respectively). An IgG2a-Fc fused to antigen (*Pf*MSP1~19~-IgG2a-Fc) was used as an internal negative control (![](fx2.gif), ![](fx3.gif) 50 or 100 μg/ml respectively).](gr7){#f0035}

![Passive transfer of mouse *Pf*MSP1~19~-specific IgG1 does not protect mice from infection. Groups of four BALB/c wild type littermates were injected i.p. with a total dose of 1.5 mg of purified anti-*P. falciparum* mouse IgG1 (open symbols, groups 1 and 3) or with PBS-vehicle control (closed symbols, groups 2 and 4) and challenged with 5000 parasitized red blood cells (prbc) derived from 'passage' animals infected with Pb-PfM19. Similar results were obtained from two independent experiments (a--b and c--d respectively). (a) and (c) Mean weight as % of initial (mean weight from days −1, 0, +1) was assessed daily to determine if an animal had lost more than 20% of its original weight (dotted line) used as a humane end-point in accordance with Home Office regulations. (c) and (d) Seven out of eight animals treated with mIgG1-C1 succumbed to malaria infection and no significant difference was shown between the test and control groups. The percentage of parasitemia between the test and control groups was similar in both experiments.](gr8){#f0040}

###### 

Association (*K*~A~) and dissociation (*K*~D~) rate constants for the mouse (m) and human (h) IgG antibodies measured by SPR analysis.[a](#tblfn1){ref-type="table-fn"}

  Antibody    *K*~A~ (1/M)   *K*~D~ (M)
  ----------- -------------- ---------------
  mIgG1-C1    4.48 × 10^7^   2.3 × 10^−8^
  mIgG2a-C1   3.32 × 10^7^   3.01 × 10^−8^
  mIgG2b-C1   1.2 × 10^7^    8.41 × 10^−8^
  mIgG3-C1    2.33 × 10^7^   3.11 × 10^−8^
  hIgG1-C1    3.94 × 10^7^   2.3 × 10^−8^

Methodology described in [@b0125; @b0170].

[^1]: Present address: Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, UK.

[^2]: Present address: University of Nottingham, Academic Clinical Oncology, City Hospital, Nottingham NG5 1PB, UK.
